The Bull Case For Alnylam Pharmaceuticals (ALNY) Could Change Following Phase 3 ZENITH Study Launch for Zilebesiran

• Alnylam Pharmaceuticals recently announced that the first patient has been dosed in the global Phase 3 ZENITH study, evaluating zilebesiran for reducing major adverse cardiovascular events in patients with uncontrolled hypertension, in partnership with Roche.
• This milestone highlights Alnylam’s efforts to expand its RNAi therapy portfolio into cardiovascular disease, a field with significant unmet medical need, and could shape the future diversification of its product pipeline.
• We’ll explore how the initiation of this Phase 3 outcomes trial could influence Alnylam’s investment narrative and growth prospects.

Rare earth metals are the new gold rush. Find out which 38 stocks are leading the charge.

Alnylam Pharmaceuticals Investment Narrative Recap

For shareholders in Alnylam Pharmaceuticals, belief in the company’s ability to expand its RNAi platform beyond rare diseases into broader markets such as cardiovascular disease is key. The ZENITH Phase 3 trial marks a step toward diversification, but it does not materially alter the primary short-term catalyst, continued robust uptake and expansion of AMVUTTRA, or the biggest risk, which remains heavy revenue reliance on the TTR franchise. This trial’s progress is more relevant to long-term pipeline evolution than immediate financial outcomes.

Among recent developments, positive Phase 3 findings for AMVUTTRA (vutrisiran) in the HELIOS-B study, specifically the reduction of gastrointestinal side effects, stand out. These results support AMVUTTRA’s competitive position, reinforcing its importance to Alnylam’s current growth narrative, as product performance and expansion efforts continue to be a core catalyst before pipeline diversification takes center stage. Yet, even with progress, one lingering concern remains…

Read the full narrative on Alnylam Pharmaceuticals (it’s free!)

Alnylam Pharmaceuticals’ outlook anticipates $7.0 billion in revenue and $1.9 billion in earnings by 2028. This scenario relies on a 41.8% annual revenue growth rate and a $2.2 billion increase in earnings from the current -$319.1 million.

Uncover how Alnylam Pharmaceuticals’ forecasts yield a $447.15 fair value, a 4% downside to its current price.

Exploring Other Perspectives

Six fair value estimates from the Simply Wall St Community span US$225.68 to US$880.05 per share, reflecting strong contrasts in expectations for Alnylam’s future. While optimism around pipeline advances persists, the risk of overdependence on AMVUTTRA continues to shape broader views on the company’s trajectory.

Explore 6 other fair value estimates on Alnylam Pharmaceuticals – why the stock might be worth as much as 89% more than the current price!

Build Your Own Alnylam Pharmaceuticals Narrative

Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

Curious About Other Options?

Don’t miss your shot at the next 10-bagger. Our latest stock picks just dropped:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com